Active Biotech AB Release: RhuDex(R) Achieves Positive Results in Clinical Phase IIa Trial

LUND, SWEDEN--(Marketwire - June 24, 2008) - Lund, Sweden, June 24, 2008 - Active Biotech AB's (OMX Nordic:ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) has achieved its objectives in a clinical phase IIa trial of the candidate drug RhuDex® for the treatment of rheumatoid arthritis.

Back to news